uniQure, Huntington's disease

Raymond James and Cantor both released bullish notes on uniQure (NASDAQ:QURE) Tuesday in the wake of news that the company ...
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 12.45% ...
The company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an ...
Crucially for the Netherlands-based biopharma company, the FDA has said that the composite Unified Huntington's Disease ...
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Qure's AMT-130 shows promising results for Huntington’s disease. Learn why QURE stock faces commercialization challenges ...
Leerink raised the firm’s price target on uniQure (QURE) to $44 from $26 and keeps an Outperform rating on the shares. The firm notes the ...
Qure stock surges after FDA agrees on an accelerated approval pathway for its Huntington's disease treatment, AMT-130.
Walleye Capital LLC purchased a new stake in uniQure (NASDAQ:QURE – Free Report) in the third quarter, according to the ...
After uniQure (QURE) announced they have achieved alignment with the FDA on key elements of an accelerated approval pathway for AMT-130, Stifel ...